MannKind Corp Earnings
The next earnings date for MannKind Corp is November 4, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of MannKind Corp Earnings
| 11/04/2026 | $-0.08 |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
MannKind Corp Earnings: Historical
| 08/05/2026 | After Market | $-0.06 | -200.00% |
| 05/07/2026 | --- | $-0.02 | -398.51% |
| 02/26/2026 | Before Market | $-0.05 | -400.00% |
| 11/05/2025 | Before Market | $0.03 | 200.00% |
| 08/06/2025 | Before Market | $0.05 | -37.50% |
| 05/06/2025 | Before Market | $0.04 | -33.33% |
| 02/26/2025 | After Market | $0.03 | -25.00% |
| 11/07/2024 | After Market | $0.04 | 33.33% |
| 08/07/2024 | Before Market | $-0.01 | -200.00% |
| 05/08/2024 | After Market | $0.04 | 33.33% |
More About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
“MannKind Corp Earnings” Can Refer to the MannKind Corp Earnings Date
Some people say “MannKind Corp earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my MannKind Corp position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning MannKind Corp Stock on the Earnings Date
If you own MannKind Corp stock (MNKD) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for MannKind Corp might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading MannKind Corp shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Owning MannKind Corp Options on the Earnings Date
If you own MannKind Corp options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
In addition, the extrinsic values of MannKind Corp options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own MannKind Corp options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.
This makes sense considering that prices are often more volatile on earnings dates for MannKind Corp. That potential volatility is a key factor that affects the premium cost of owning options.
Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of MannKind Corp options often go down. This is sometimes referred to as volatility crush.
Learning More MannKind Corp Earnings
You can contact us any time if you would like to ask questions about MannKind Corp earnings or anything else related to the stock market.